By Katherine Hamilton
Rhythm Pharmaceuticals said Friday that its weight-loss treatment gained expanded approval from the U.S. Food and Drug Administration to include children as young as two years old.
The drug, called imcivree, is designed to reduce excess body weight and maintain weight reduction long-term for patients with obesity due to Bardet-Biedl syndrome (BBS) or pro-opiomelanocortin, said the Boston-based company.
Imcivree first received FDA approval in 2020 for patients ages 6 and older.
Results from clinical trials of the medicine show significant and sustained reductions in weight and hunger, said the company.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
December 20, 2024 15:20 ET (20:20 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。